Lycia Therapeutics targets $938 million valuation in US IPO
Drug developer Lycia Therapeutics announced it is targeting a valuation of up to $937.7 million in its U.S. initial public offering, joining other biotech companies entering the IPO market.
3 sourcesDrug development
00